PMID- 38035054
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231202
IS  - 2223-8956 (Electronic)
IS  - 1016-3190 (Print)
IS  - 1016-3190 (Linking)
VI  - 35
IP  - 4
DP  - 2023 Oct-Dec
TI  - Treating overactive bladder symptoms after transurethral prostatic surgery for 
      benign prostatic hyperplasia - Which medication to choose?
PG  - 312-316
LID - 10.4103/tcmj.tcmj_123_23 [doi]
AB  - OBJECTIVES: Overactive bladder (OAB) symptoms are often encountered in patients 
      after transurethral resection of the prostate (TUR-P) or transurethral incision 
      of the prostate (TUI-P) for benign prostatic obstruction (BPO). Either 
      antimuscarinics or beta-3 agonist has been found effective in relieving OAB 
      symptoms. However, urologists usually do not prescribe such medication 
      immediately after TUR-P or TUI-P to avoid an increase in postvoid residual and 
      risk of urinary tract infection. If OAB medication can be used and adverse events 
      (AEs) can be reduced to minimum, patients' quality of life after bladder outlet 
      obstruction surgery could be improved. This study compared the safety and 
      efficacy between solifenacin and mirabegron in men undergoing TUR-P or TUI-P. 
      MATERIALS AND METHODS: This prospective, randomized trial compared the safety and 
      efficacy of OAB medication on the reduction in Urgency Severity Score (USS), OAB 
      Symptoms Score (OABSS), International Prostate Symptom Score, and urgency urinary 
      incontinence episodes in men with BPO undergoing surgical intervention. All 
      patients could void smoothly after catheter removal and were randomly received 
      daily solifenacin 5 mg, mirabegron 50 mg, or no interventions for 4 weeks. At 2 
      and 4 weeks postoperatively, participants' OAB symptoms and AEs were evaluated. 
      RESULTS: A total of 57 men were enrolled in this study with a mean age of 70.8 +/- 
      6.1 years. At 2 weeks postoperatively, USS (1.56 +/- 1.72 vs. 2.39 +/- 1.72 vs. 2.26 
      +/- 1.73, P < 0.011) and OABSS (5.33 +/- 3.65 vs. 7.67 +/- 4.19 vs. 8.58 +/- 4.31, P < 
      0.000) were significantly reduced in patients taking solifenacin, mirabegron, or 
      control, respectively. Two patients in the solifenacin group developed urinary 
      retention. However, the changes of variables at 4 weeks postoperatively were 
      insignificant among the three groups. CONCLUSION: Solifenacin and mirabegron are 
      two different drug classes both equally effective in treating immediate OAB 
      symptoms after TUR-P or TUI-P. However, OAB symptoms could be relieved at 4 weeks 
      without any medication. Considering AEs, beta-3 agonist has a more favorable safety 
      profile than antimuscarinics.
CI  - Copyright: (c) 2023 Tzu Chi Medical Journal.
FAU - Lee, Cheng-Ling
AU  - Lee CL
AD  - Department of Urology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical 
      Foundation and Tzu Chi University, Hualien, Taiwan.
FAU - Kuo, Hann-Chorng
AU  - Kuo HC
AD  - Department of Urology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical 
      Foundation and Tzu Chi University, Hualien, Taiwan.
LA  - eng
PT  - Journal Article
DEP - 20230822
PL  - India
TA  - Tzu Chi Med J
JT  - Tzu chi medical journal
JID - 101770275
PMC - PMC10683516
OTO - NOTNLM
OT  - Benign prostatic hyperplasia
OT  - Mirabegron
OT  - Overactive bladder
OT  - Solifenacin
OT  - Transurethral resection of the prostate
COIS- Dr. Hann-Chorng Kuo, an editorial board member at Tzu Chi Medical Journal, had no 
      role in the peer review process of or decision to publish this article. The other 
      author declared no conflicts of interest in writing this paper.
EDAT- 2023/11/30 18:45
MHDA- 2023/11/30 18:46
PMCR- 2023/08/22
CRDT- 2023/11/30 17:42
PHST- 2023/05/11 00:00 [received]
PHST- 2023/05/24 00:00 [revised]
PHST- 2023/06/13 00:00 [accepted]
PHST- 2023/11/30 18:46 [medline]
PHST- 2023/11/30 18:45 [pubmed]
PHST- 2023/11/30 17:42 [entrez]
PHST- 2023/08/22 00:00 [pmc-release]
AID - TCMJ-35-312 [pii]
AID - 10.4103/tcmj.tcmj_123_23 [doi]
PST - epublish
SO  - Tzu Chi Med J. 2023 Aug 22;35(4):312-316. doi: 10.4103/tcmj.tcmj_123_23. 
      eCollection 2023 Oct-Dec.